Price Gouging Tests the Limits of Free Competition


Last month, a pair of brothers in Tennessee made headlines for stockpiling hoards of hand sanitizer and bacterial wipes purchased from retailers during a “1,300-mile road trip across Tennessee and into Kentucky”.  The entrepreneurs then listed the items on Amazon, often for many times the original purchase price.  Throughout March, similar stories abounded – while physical store shelves emptied, online listings for basic sanitation products multiplied, and at enormous mark ups.   The problem became so severe that the state of New York got into the hand sanitizer business.  

Widespread outcry from consumer groups and government officials has focused attention on “price gouging,” a practice as odious as it is hard to define.  About 40 states have laws against price gouging, often triggered by a governor’s declaration of a state of emergency.  Some of those laws define price gouging as a price increase above a certain amount, while others ban price increases that are not deemed “reasonable.”  But there is no federal laws or guidelines on price gouging.  On March 23, President Trump issued an executive order instructing the Department of Justice to prioritize “the detection, investigation, and prosecution of fraudulent activity and price gouging related to medical resources needed to respond to the coronavirus.”  But it was not until last week that federal officials brought the first-ever price gouging case under the Defense Production Act of 1950, against a New York retailer.  

But varying definitions and a rapidly shifting marketplace can make identification of actual price gouging difficult.  A former DoJ attorney noted that price gouging rules “are different from the traditional goals of antitrust laws, [because] [t]hey aren't promoting competition and free-market principles. They are putting caps on prices, which is not typical. But that's the world we're in now.”

Now, the Tennessee brothers have been compelled to donate their hoarded goods, in connection with a settlement of state charges.  And even civil litigants are attempting to address the issue: last week, 3M won a restraining order against distributor Performance Supply LLC for selling 3M products at exorbitant prices: “The lawsuits don’t claim the defendants are selling fake masks, but rather that they are using the 3M trademark and other misleading tactics to dupe buyers into thinking their sky-high prices are somehow authorized by 3M.”  Meanwhile, a California class action accuses Amazon of price gouging on entire categories of “essential goods”.

With this new found attention, Proposal for new federal laws are now making their way through Congress.  It remains to be seen whether Congress’ attention span extends longer than the current crisis. 

About Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP focuses on complex civil litigation, including securities, antitrust, wage and hour and consumer class actions as well as shareholder derivative and merger and transactional litigation. The firm is headquartered in New York, and maintains offices in California, Georgia and Pennsylvania.

Since its founding in 1995, Faruqi & Faruqi, LLP has served as lead or co-lead counsel in numerous high-profile cases which ultimately provided significant recoveries to investors, direct purchasers, consumers and employees.

To schedule a free consultation with our attorneys and to learn more about your legal rights, call our offices today at (877) 247-4292 or (212) 983-9330.

About Adam Steinfeld

Adam Steinfeld is a Partner in Faruqi & Faruqi, LLP's New York office. He practices in the area of antitrust litigation with a focus on competition in the pharmaceutical industry. Mr. Steinfeld has litigated successfully with significant contributions in In re Buspirone Patent & Antitrust Litigation, MDL No. 1410 (S.D.N.Y.) ($220M settlement); In re Cardizem CD Antitrust Litigation, No. 99-MD-1278 (E.D. Mich.) ($110M settlement); In re Relafen Antitrust Litigation, No. 01-12239 (D. Mass.) ($175M settlement); In re Remeron Direct Purchaser Antitrust Litigation, No. 03-cv-0085 (D.N.J.) ($75M settlement); In re Terazosin Hydrochloride Antitrust Litigation, No. 99-MDL-1317 (S.D. Fla.) ($72.5M settlement); In re Tricor Direct Purchaser Antitrust Litig., No. 05-340 (D. Del.) ($250M settlement); and Mylan Pharms., Inc. v. Warner Chilcott, No. 12-cv-3824 (E.D. Pa.) ($12 million settlement).

Tags: faruqi & faruqi, investigation, news, litigation, settlement notice, case, faruqi law, faruqi blog, faruqilaw, Adam Steinfeld, antitrust litigation Adam Steinfeld Adam Steinfeld
Partner at Faruqi & Faruqi, LLP

New York office
Tel: (212) 983-9330
Fax: (212) 983-9331
E-mail: asteinfeld@faruqilaw.com
Social: LinkedIn

Finding us

Our Offices


Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331

California

1901 Avenue of the Stars Suite 1060
Los Angeles, California 90067
(424) 256-2884
(424) 256-2885

Georgia

3565 Piedmont Road NE Building Four, Suite 380
Atlanta, Georgia 30305
(404) 847-0617
(404) 506-9534

Pennsylvania

1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania